On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.
According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.